EICHOR
● Recruiting
A IIT Study of 177Lu-DOTA-SNA040
Condition: Advanced Solid Tumors (Such as Gastric Cancer) · Advanced Solid Tumors (Such as Adenocarcinoma at the Gastroesophageal Junction) · Advanced Solid Tumors (Such as Pancreatic Cancer) · Sponsor: SmartNuclide Biopharma
About this study
This clinical trial is a single-center, open-label, non-randomized, first-in-human (FIH), dose-escalation study evaluating the safety, tolerability, and preliminary efficacy of 177Lu-DOTA-SNA040 in patients with advanced Claudin18.2-positive solid tumors (e.g., gastric cancer, gastroesophageal junction adenocarcinoma, pancreatic cancer, cholangiocarcinoma, etc.) who have disease progression following first-line therapy.
This description comes directly from the study's public registry record.
Talk to the study team
shaoli song, doctor · 0512-67229125 · mengru.wu@smartnucl.com
Always discuss trial participation with your own doctor first.
Locations (1)
| Fudan University Shanghai Cancer Center | Shanghai, Shanghai Municipality, China | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07595237